Results 91 to 93 of about 4,757 (93)
Some of the next articles are maybe not open access.
Blood, 2000
Abstract Cytochrome P-450 2C9 is the principle enzyme that terminates the anticoagulant effect of warfarin. Genetic polymorphisms inCYP2C9 producing variants with altered catalytic properties have been identified. Patients (n = 561) with a target international normalized ratio (INR) of 2.5 who had been treated with warfarin for more than
J, Taube, D, Halsall, T, Baglin
openaire +2 more sources
Abstract Cytochrome P-450 2C9 is the principle enzyme that terminates the anticoagulant effect of warfarin. Genetic polymorphisms inCYP2C9 producing variants with altered catalytic properties have been identified. Patients (n = 561) with a target international normalized ratio (INR) of 2.5 who had been treated with warfarin for more than
J, Taube, D, Halsall, T, Baglin
openaire +2 more sources
Thrombosis and Haemostasis, 2003
Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome P-450 CYP2C9 -
Eduardo Rocha +4 more
openaire +1 more source
Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome P-450 CYP2C9 -
Eduardo Rocha +4 more
openaire +1 more source
Khalij-Libya Journal of Dental and Medical Research
CYP2C9 gene encodes an enzyme that metabolizes a variety of drugs. Genetic variations in the CYP2C9 enzyme, particularly the CYP2C9*2 and CYP2C9*3 polymorphisms, can significantly impact enzyme activity, resulting in variations in drug metabolism and response among individuals who carry them.
openaire +1 more source
CYP2C9 gene encodes an enzyme that metabolizes a variety of drugs. Genetic variations in the CYP2C9 enzyme, particularly the CYP2C9*2 and CYP2C9*3 polymorphisms, can significantly impact enzyme activity, resulting in variations in drug metabolism and response among individuals who carry them.
openaire +1 more source